Product image of Memantina Atb (Memantine Hydrochloride) supplied by GNH India

Memantina Atb

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantina Atb (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Memantina Atb, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is employed in the management of Alzheimer’s disease, primarily in patients with mild to moderate cognitive impairment. The medication is formulated to cross the blood‑brain barrier, targeting neuronal pathways implicated in excitotoxic damage.

GNH India supplies Memantina Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across multiple markets.

Manufacturer / TM Owner

Antibiotice Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Memantina Atb, a NMDA receptor antagonist, is indicated for conditions within the Alzheimer’s disease spectrum.

  • Mild-to-moderate Alzheimer’s disease: modest improvement in cognition and daily functioning.
  • Moderate Alzheimer’s disease: helps maintain ability to perform instrumental activities of daily living.
  • Alzheimer’s disease with behavioral symptoms: may reduce agitation and improve overall patient management.

How It Works

  • Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury. This modulation of glutamatergic transmission helps preserve synaptic function and slows the progression of neurodegeneration associated with Alzheimer’s disease in affected brain regions.

Side Effects

Memantina Atb may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects

  • Seizures: occurrence of convulsive episodes.
  • Allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Hallucinations or psychosis: visual or auditory disturbances.

Precautions & Warnings

When prescribing Memantina Atb, clinicians should consider several safety measures and monitoring requirements.

  • Renal impairment: assess kidney function before initiation and adjust as needed.
  • Hepatic disease: monitor liver enzymes due to potential metabolism involvement.
  • Concomitant CNS depressants: observe for enhanced sedation or dizziness.
  • History of seizures: use with caution and monitor for seizure activity.
  • Pregnancy and lactation: evaluate risk‑benefit as safety data are limited.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Memantina Atb can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Amantadine: combined NMDA antagonism may increase risk of neuropsychiatric effects.
  • High‑dose ketamine: additive NMDA blockade can lead to severe CNS depression.

Moderate Interactions (Monitor Closely)

  • Anticholinergic agents: may exacerbate cognitive side effects.
  • Carbamazepine: enzyme induction may reduce memantine plasma levels.
  • NSAIDs: concurrent use may increase risk of dizziness or headache.
  • Alcohol: may potentiate central nervous system depression.

Frequently Asked Questions

Memantina Atb contains memantine hydrochloride and is prescribed for the symptomatic treatment of Alzheimer’s disease, particularly in patients with mild to moderate cognitive decline. It helps improve or stabilize cognition, memory, and daily functioning by modulating glutamatergic activity in the brain.

Memantine acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx caused by prolonged glutamate stimulation. This reduces excitotoxic neuronal damage, helping to preserve synaptic function and slow the neurodegenerative processes associated with Alzheimer’s disease.

The specific dose of Memantina Atb is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Dosage regimens may be titrated gradually, and the prescriber will provide individualized instructions.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Memantina Atb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class is acetylcholinesterase inhibitors such as donepezil. While those agents increase acetylcholine levels, memantine modulates glutamate activity. Clinicians may choose memantine for patients who cannot tolerate cholinergic side effects or as add‑on therapy to address different pathogenic pathways.

Memantina Atb should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually as a whole tablet swallowed with water. It is typically taken once daily, but the exact schedule and any dose adjustments are determined by the prescribing physician.

Serious adverse events, although uncommon, include seizures, severe allergic reactions such as anaphylaxis, and neuropsychiatric effects like hallucinations or psychosis. Patients should be monitored for these symptoms, and treatment should be discontinued if they occur.

Memantina Atb is contraindicated in patients with known hypersensitivity to memantine or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other strong NMDA antagonists.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT